117 related articles for article (PubMed ID: 38359316)
1. Design, Synthesis, and Molecular Docking of Novel Miscellaneous Chalcones as p38α Mitogen-Activated Protein Kinase Inhibitors.
Zeid MM; El-Badry OM; Elmeligie S; Hassan RA
Chem Biodivers; 2024 Apr; 21(4):e202400077. PubMed ID: 38359316
[TBL] [Abstract][Full Text] [Related]
2. Discovery of thiazole-based-chalcones and 4-hetarylthiazoles as potent anticancer agents: Synthesis, docking study and anticancer activity.
Farghaly TA; Masaret GS; Muhammad ZA; Harras MF
Bioorg Chem; 2020 May; 98():103761. PubMed ID: 32200332
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and in vitro antiproliferative activity of certain novel pyrazolo[3,4-b]pyridines with potential p38α MAPK-inhibitory activity.
Farahat AA; Samir EM; Zaki MY; Serya RAT; Abdel-Aziz HA
Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100302. PubMed ID: 34796536
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of halogenated phenoxychalcones and their corresponding pyrazolines as cytotoxic agents in human breast cancer.
Halim PA; Hassan RA; Mohamed KO; Hassanin SO; Khalil MG; Abdou AM; Osman EO
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):189-201. PubMed ID: 34894967
[TBL] [Abstract][Full Text] [Related]
5. Design and molecular modeling of novel P38α MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds.
Abdelhafez OM; Ahmed EY; Abdel Latif NA; Arafa RK; Abd Elmageed ZY; Ali HI
Bioorg Med Chem; 2019 Apr; 27(7):1308-1319. PubMed ID: 30792101
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and molecular docking study of new benzofuran and furo[3,2-g]chromone-based cytotoxic agents against breast cancer and p38α MAP kinase inhibitors.
Amin KM; Syam YM; Anwar MM; Ali HI; Abdel-Ghani TM; Serry AM
Bioorg Chem; 2018 Feb; 76():487-500. PubMed ID: 29310080
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and molecular docking studies of new furochromone derivatives as p38α MAPK inhibitors targeting human breast cancer MCF-7 cells.
Amin KM; Syam YM; Anwar MM; Ali HI; Abdel-Ghani TM; Serry AM
Bioorg Med Chem; 2017 Apr; 25(8):2423-2436. PubMed ID: 28291685
[TBL] [Abstract][Full Text] [Related]
8. 3D-QSAR and molecular docking studies on fused pyrazoles as p38α mitogen-activated protein kinase inhibitors.
Lan P; Huang ZJ; Sun JR; Chen WM
Int J Mol Sci; 2010 Sep; 11(9):3357-74. PubMed ID: 20957100
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
[TBL] [Abstract][Full Text] [Related]
10. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and QSAR study of 2'-hydroxy-4'-alkoxy chalcone derivatives that exert cytotoxic activity by the mitochondrial apoptotic pathway.
Marquina S; Maldonado-Santiago M; Sánchez-Carranza JN; Antúnez-Mojica M; González-Maya L; Razo-Hernández RS; Alvarez L
Bioorg Med Chem; 2019 Jan; 27(1):43-54. PubMed ID: 30482548
[TBL] [Abstract][Full Text] [Related]
12. Imidazopyridine chalcones as potent anticancer agents: Synthesis, single-crystal X-ray, docking, DFT and SAR studies.
Soumyashree DK; Reddy DS; Nagarajaiah H; Naik L; Savanur HM; Shilpa CD; Sunitha Kumari M; Shanavaz H; Padmashali B
Arch Pharm (Weinheim); 2023 Jul; 356(7):e2300106. PubMed ID: 37208792
[TBL] [Abstract][Full Text] [Related]
13. Molecular Docking Study, Cytotoxicity, Cell Cycle Arrest and Apoptotic Induction of Novel Chalcones Incorporating Thiadiazolyl Isoquinoline in Cervical Cancer.
Tantawy MA; Sroor FM; Mohamed MF; El-Naggar ME; Saleh FM; Hassaneen HM; Abdelhamid IA
Anticancer Agents Med Chem; 2020; 20(1):70-83. PubMed ID: 31696811
[TBL] [Abstract][Full Text] [Related]
14. Identification of new 5-(2,6-dichlorophenyl)-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-7-carboxylic acids as p38α MAPK inhibitors: Design, synthesis, antitumor evaluation, molecular docking and in silico studies.
El-Wakil MH; El-Dershaby HA; Ghazallah RA; El-Yazbi AF; Abd El-Razik HA; Soliman FSG
Bioorg Chem; 2024 Apr; 145():107226. PubMed ID: 38377818
[TBL] [Abstract][Full Text] [Related]
15. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
16. Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: Design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR/Topo-1 inhibition.
Halim PA; Sharkawi SMZ; Labib MB
Bioorg Chem; 2023 Feb; 131():106273. PubMed ID: 36444790
[TBL] [Abstract][Full Text] [Related]
17. Structural optimization of 4-(imidazol-5-yl)pyridine derivatives affords broad-spectrum anticancer agents with selective B-RAF
Ali EMH; Mersal KI; Ammar UM; Zaraei SO; Abdel-Maksoud MS; El-Gamal MI; Haque MM; Das T; Kim EE; Lee JS; Lee KH; Kim HK; Oh CH
Eur J Pharm Sci; 2022 Apr; 171():106115. PubMed ID: 34995782
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and molecular docking study of novel quinoline-based bis-chalcones as potential antitumor agents.
Insuasty D; García S; Abonia R; Insuasty B; Quiroga J; Nogueras M; Cobo J; Borosky GL; Laali KK
Arch Pharm (Weinheim); 2021 Sep; 354(9):e2100094. PubMed ID: 34050547
[TBL] [Abstract][Full Text] [Related]
19. Novel benzotriazole N-acylarylhydrazone hybrids: Design, synthesis, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and FAK inhibition.
Kassab AE; Hassan RA
Bioorg Chem; 2018 Oct; 80():531-544. PubMed ID: 30014921
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, Anticancer Assessment, and Molecular Docking of Novel Chalcone-Thienopyrimidine Derivatives in HepG2 and MCF-7 Cell Lines.
Safwat GM; Hassanin KMA; Mohammed ET; Ahmed EK; Abdel Rheim MR; Ameen MA; Abdel-Aziz M; Gouda AM; Peluso I; Almeer R; Abdel-Daim MM; Abdel-Wahab A
Oxid Med Cell Longev; 2021; 2021():4759821. PubMed ID: 35003514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
